News and Events

October 13, 2020
Angstrom Bio Launches AMPD™, a Platform for High-Accuracy, High-Frequency COVID-19 and Respiratory Pathogen Testing
Angstrom Bio, Inc. today announces the launch of AMPD™, its nanopore sequencing- and machine learning-powered platform for high-accuracy, high-frequency, low-cost COVID-19 and respiratory pathogen testing. AMPD leverages the extreme resolution and bandwidth of nanopore sequencing to provide the accuracy and volume necessary to detect the earliest stages of exposure to pathogens like SARS-CoV-2 and influenza, and to enable schools and places of work to reopen safely and confidently.